Compare Aurobindo Pharma with ALEMBIC PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs ALEMBIC PHARMA - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA ALEMBIC PHARMA AUROBINDO PHARMA/
ALEMBIC PHARMA
 
P/E (TTM) x 10.6 16.1 65.7% View Chart
P/BV x 2.3 3.7 62.0% View Chart
Dividend Yield % 0.5 1.0 53.0%  

Financials

 AUROBINDO PHARMA   ALEMBIC PHARMA
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-18
ALEMBIC PHARMA
Mar-19
AUROBINDO PHARMA/
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs809664 121.8%   
Low Rs504412 122.2%   
Sales per share (Unadj.) Rs281.1208.7 134.7%  
Earnings per share (Unadj.) Rs41.431.0 133.4%  
Cash flow per share (Unadj.) Rs50.937.1 137.1%  
Dividends per share (Unadj.) Rs2.505.50 45.5%  
Dividend yield (eoy) %0.41.0 37.3%  
Book value per share (Unadj.) Rs199.4144.2 138.2%  
Shares outstanding (eoy) m585.88188.52 310.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.32.6 90.6%   
Avg P/E ratio x15.917.4 91.4%  
P/CF ratio (eoy) x12.914.5 89.0%  
Price / Book Value ratio x3.33.7 88.2%  
Dividend payout %6.017.7 34.1%   
Avg Mkt Cap Rs m384,630101,461 379.1%   
No. of employees `00017.3NA-   
Total wages/salary Rs m21,3087,467 285.4%   
Avg. sales/employee Rs Th9,500.7NM-  
Avg. wages/employee Rs Th1,229.4NM-  
Avg. net profit/employee Rs Th1,397.9NM-  
INCOME DATA
Net Sales Rs m164,66639,347 418.5%  
Other income Rs m1,02094 1,087.2%   
Total revenues Rs m165,68639,441 420.1%   
Gross profit Rs m37,7188,736 431.8%  
Depreciation Rs m5,5801,152 484.2%   
Interest Rs m777184 422.2%   
Profit before tax Rs m32,3807,493 432.1%   
Minority Interest Rs m3111 290.7%   
Prior Period Items Rs m0-93 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m8,1831,568 522.0%   
Profit after tax Rs m24,2295,844 414.6%  
Gross profit margin %22.922.2 103.2%  
Effective tax rate %25.320.9 120.8%   
Net profit margin %14.714.9 99.1%  
BALANCE SHEET DATA
Current assets Rs m121,87819,577 622.5%   
Current liabilities Rs m86,80614,896 582.7%   
Net working cap to sales %21.311.9 179.0%  
Current ratio x1.41.3 106.8%  
Inventory Days Days13090 144.7%  
Debtors Days Days6845 150.8%  
Net fixed assets Rs m81,03727,097 299.1%   
Share capital Rs m586377 155.4%   
"Free" reserves Rs m116,21826,811 433.5%   
Net worth Rs m116,80427,188 429.6%   
Long term debt Rs m4,5124,993 90.4%   
Total assets Rs m211,05247,778 441.7%  
Interest coverage x42.741.7 102.3%   
Debt to equity ratio x00.2 21.0%  
Sales to assets ratio x0.80.8 94.7%   
Return on assets %11.812.6 93.9%  
Return on equity %20.721.5 96.5%  
Return on capital %27.423.6 115.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m80,72719,453 415.0%   
Fx outflow Rs m34,7006,065 572.2%   
Net fx Rs m46,02713,388 343.8%   
CASH FLOW
From Operations Rs m19,5488,120 240.8%  
From Investments Rs m-19,570-7,556 259.0%  
From Financial Activity Rs m8,642590 1,463.7%  
Net Cashflow Rs m8,9221,153 773.6%  

Share Holding

Indian Promoters % 54.1 74.1 73.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 2.9 274.1%  
FIIs % 27.7 9.1 304.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 13.9 73.4%  
Shareholders   69,601 49,328 141.1%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   GLENMARK PHARMA  FULFORD INDIA  DR. REDDYS LAB  DIVIS LABORATORIES  UNICHEM LAB  

Compare AUROBINDO PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 87 Points Higher; Telecom and Auto Stocks Witness Buying(Closing)

Indian share markets ended their trading session marginally higher. On the sectoral front, gains were seen in the telecom sector and auto sector.

Related Views on News

AUROBINDO PHARMA Surges by 6%; BSE HEALTHCARE Index Up 1.3% (Market Updates)

Oct 14, 2019 | Updated on Oct 14, 2019

AUROBINDO PHARMA share price has surged by 6% and its current market price is Rs 464. The BSE HEALTHCARE is up by 1.3%. The top gainers in the BSE HEALTHCARE Index is AUROBINDO PHARMA (up 5.7%). The top losers are FDC LTD. and DIVIS LABORATORIES (down 0.3%).

ALEMBIC PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 36.4% (Quarterly Result Update)

Aug 21, 2019 | Updated on Aug 21, 2019

For the quarter ended June 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 36.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.0% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

ALEMBIC PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 13, 2019 | Updated on Jun 13, 2019

Here's an analysis of the annual report of ALEMBIC PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

What if Indiabulls Housing Finance and Yes Bank Do Not Rebound?(Profit Hunter)

Oct 1, 2019

How long should you wait for fallen blue chips like Yes Bank and Indiabulls Housing Finance to rebound?

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

Foreign Money is Chasing Indian Stocks Once Again(The 5 Minute Wrapup)

Oct 4, 2019

Around Rs 75 billion poured into the Indian stock market in the month of September.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Oct 14, 2019 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 8-QTR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS